The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer-Reference-Cited by-同舟云学术

The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer

Published:2014-02-22 Issue:5 Volume:140 Page:849-857
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Zhao Jingya,Wang Xiaoying,Xue Liang,Xu Nuo,Ye Xin,Zeng Haiying,Lu Shaohua,Huang Jie,Akesu Sujie,Xu Chen,He Deming,Tan Yunshan,Hong Qunying,Wang Qun,Zhu Guanshan,Hou Yingyong,Zhang Xin

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-014-1618-2.pdf

Reference23 articles.

1. Azuma K, Okamoto I, Kawahara A et al (2012) Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. J Thorac Oncol 7(1):122–127

2. Bai H, Wang Z, Chen K et al (2012) Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 30(25):3077–3083

3. Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29(21):2866–2874

4. Inoue A, Suzuki T, Fukuhara T et al (2006) Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24(21):3340–3346

5. Kato Y, Peled N, Wynes MW et al (2010) Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 5(10):1551–1558

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ΔCT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non–Small-Cell Lung Cancer: A Multi-Center Retrospective Study;Frontiers in Molecular Biosciences;2021-10-08

2. Antagonism between HTRA3 and TGFβ1 Contributes to Metastasis in Non–Small Cell Lung Cancer;Cancer Research;2019-04-02

3. EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry;BMC Pulmonary Medicine;2018-08-09

4. Comparison of direct sequencing and amplification refractory mutation system for detecting epidermal growth factor receptor mutation in non-small-cell lung cancer patients: a systematic review and meta-analysis;Oncotarget;2017-07-08

5. Immunohistochemistry for EGFR Mutation Detection in Non–Small-Cell Lung Cancer;Clinical Lung Cancer;2017-05